CPHI vs. PRPH, NERV, SPRB, CING, NRSN, BGXX, IMNN, HCWB, AIM, and CRVO
Should you be buying China Pharma stock or one of its competitors? The main competitors of China Pharma include ProPhase Labs (PRPH), Minerva Neurosciences (NERV), Spruce Biosciences (SPRB), Cingulate (CING), NeuroSense Therapeutics (NRSN), Bright Green (BGXX), Imunon (IMNN), HCW Biologics (HCWB), AIM ImmunoTech (AIM), and CervoMed (CRVO). These companies are all part of the "pharmaceutical products" industry.
China Pharma vs.
ProPhase Labs (NASDAQ:PRPH) and China Pharma (NYSE:CPHI) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their dividends, earnings, risk, media sentiment, institutional ownership, profitability, community ranking, analyst recommendations and valuation.
China Pharma has lower revenue, but higher earnings than ProPhase Labs.
In the previous week, China Pharma had 1 more articles in the media than ProPhase Labs. MarketBeat recorded 1 mentions for China Pharma and 0 mentions for ProPhase Labs. China Pharma's average media sentiment score of 0.24 beat ProPhase Labs' score of 0.00 indicating that China Pharma is being referred to more favorably in the news media.
ProPhase Labs presently has a consensus price target of $11.00, suggesting a potential upside of 1,706.24%. Given ProPhase Labs' stronger consensus rating and higher probable upside, equities analysts clearly believe ProPhase Labs is more favorable than China Pharma.
China Pharma has a net margin of -85.56% compared to ProPhase Labs' net margin of -217.64%. ProPhase Labs' return on equity of -62.92% beat China Pharma's return on equity.
ProPhase Labs received 114 more outperform votes than China Pharma when rated by MarketBeat users. Likewise, 50.00% of users gave ProPhase Labs an outperform vote while only 0.00% of users gave China Pharma an outperform vote.
ProPhase Labs has a beta of -0.3, suggesting that its share price is 130% less volatile than the S&P 500. Comparatively, China Pharma has a beta of 0.6, suggesting that its share price is 40% less volatile than the S&P 500.
9.5% of ProPhase Labs shares are owned by institutional investors. 20.7% of ProPhase Labs shares are owned by company insiders. Comparatively, 17.3% of China Pharma shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.
Summary
ProPhase Labs beats China Pharma on 10 of the 16 factors compared between the two stocks.
Get China Pharma News Delivered to You Automatically
Sign up to receive the latest news and ratings for CPHI and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
China Pharma Competitors List
Related Companies and Tools
This page (NYSE:CPHI) was last updated on 1/22/2025 by MarketBeat.com Staff
Free CPHI Stock Alerts